Table of Contents Author Guidelines Submit a Manuscript
Journal of Diabetes Research
Volume 2017 (2017), Article ID 5063239, 8 pages
https://doi.org/10.1155/2017/5063239
Review Article

Metformin Improves Overall Survival of Colorectal Cancer Patients with Diabetes: A Meta-Analysis

Department of Gastrointestinal Surgery, China-Japan Friendship Hospital, Beijing 100029, China

Correspondence should be addressed to Li Song; moc.361@78yyhyrz and Wenyue Wang; moc.duolci@080euyneww

Received 5 September 2016; Accepted 9 January 2017; Published 8 February 2017

Academic Editor: Kezhong Zhang

Copyright © 2017 Fanqiang Meng et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. GLOBOCAN 2012, http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx.
  2. American Cancer Society, Colorectal Cancer Facts & Figures 2014–2016, American Cancer Society, Atlanta, Ga, USA, 2014.
  3. V. Walter, L. Jansen, A. Ulrich et al., “Alcohol consumption and survival of colorectal cancer patients: a population-based study from Germany,” The American Journal of Clinical Nutrition, vol. 103, no. 6, pp. 1497–1506, 2016. View at Publisher · View at Google Scholar · View at Scopus
  4. B. Doleman, K. T. Mills, S. Lim, M. D. Zelhart, and G. Gagliardi, “Body mass index and colorectal cancer prognosis: a systematic review and meta-analysis,” Techniques in Coloproctology, vol. 20, no. 8, pp. 517–535, 2016. View at Publisher · View at Google Scholar · View at Scopus
  5. Y. K. Jeong, M.-S. Kim, J. Y. Lee, E. H. Kim, and H. Ha, “Metformin radiosensitizes p53-deficient colorectal cancer cells through induction of G2/M arrest and inhibition of DNA repair proteins,” PLoS ONE, vol. 10, no. 11, Article ID e0143596, 2015. View at Publisher · View at Google Scholar · View at Scopus
  6. Y.-C. Huang, J.-K. Lin, W.-S. Chen et al., “Diabetes mellitus negatively impacts survival of patients with colon cancer, particularly in stage II disease,” Journal of Cancer Research and Clinical Oncology, vol. 137, no. 2, pp. 211–220, 2011. View at Publisher · View at Google Scholar · View at Scopus
  7. X. Liu, J. Ji, K. Sundquist, J. Sundquist, and K. Hemminki, “The impact of type 2 diabetes mellitus on cancer-specific survival: a follow-up study in Sweden,” Cancer, vol. 118, no. 5, pp. 1353–1361, 2012. View at Publisher · View at Google Scholar · View at Scopus
  8. L. V. van de Poll-Franse, H. R. Haak, J. W. W. Coebergh, M. L. G. Janssen-Heijnen, and V. E. P. P. Lemmens, “Disease-specific mortality among stage I-III colorectal cancer patients with diabetes: a large population-based analysis,” Diabetologia, vol. 55, no. 8, pp. 2163–2172, 2012. View at Publisher · View at Google Scholar · View at Scopus
  9. S. Luo, J. Y. Li, L. N. Zhao et al., “Diabetes mellitus increases the risk of colorectal neoplasia: an updated meta-analysis,” Clinics and Research in Hepatology and Gastroenterology, vol. 40, no. 1, pp. 110–123, 2016. View at Publisher · View at Google Scholar
  10. K. T. Mills, C. F. Bellows, A. E. Hoffman, T. N. Kelly, and G. Gagliardi, “Diabetes mellitus and colorectal cancer prognosis: a meta-analysis,” Diseases of the Colon and Rectum, vol. 56, no. 11, pp. 1304–1319, 2013. View at Publisher · View at Google Scholar · View at Scopus
  11. Metformin hydrochloride, https://www.drugs.com/monograph/metformin-hydrochloride.html.
  12. G. Zhou, R. Myers, Y. Li et al., “Role of AMP-activated protein kinase in mechanism of metformin action,” The Journal of Clinical Investigation, vol. 108, no. 8, pp. 1167–1174, 2001. View at Publisher · View at Google Scholar · View at Scopus
  13. R. L. Ahmed, K. H. Schmitz, K. E. Anderson, W. D. Rosamond, and A. R. Folsom, “The metabolic syndrome and risk of incident colorectal cancer,” Cancer, vol. 107, no. 1, pp. 28–36, 2006. View at Publisher · View at Google Scholar · View at Scopus
  14. E. Giovannucci, “Insulin, insulin-like growth factors and colon cancer: a review of the evidence,” Journal of Nutrition, vol. 131, supplement 11, pp. 3109S–3120S, 2001. View at Google Scholar · View at Scopus
  15. I. R. Hsu, S. P. Kim, M. Kabir, and R. N. Bergman, “Metabolic syndrome, hyperinsulinemia, and cancer,” American Journal of Clinical Nutrition, vol. 86, no. 3, pp. s867–s871, 2007. View at Google Scholar · View at Scopus
  16. J. H. Lee, T. I. Kim, S. M. Jeon, S. P. Hong, J. H. Cheon, and W. H. Kim, “The effects of metformin on the survival of colorectal cancer patients with diabetes mellitus,” International Journal of Cancer, vol. 131, no. 3, pp. 752–759, 2012. View at Publisher · View at Google Scholar · View at Scopus
  17. S. Spillane, K. Bennett, L. Sharp, and T. I. Barron, “A cohort study of metformin exposure and survival in patients with stage I-III colorectal cancer,” Cancer Epidemiology Biomarkers and Prevention, vol. 22, no. 8, pp. 1364–1373, 2013. View at Publisher · View at Google Scholar · View at Scopus
  18. R. Ramjeesingh, C. Orr, C. S. Bricks, W. M. Hopman, and N. Hammad, “A retrospective study on the role of diabetes and metformin in colorectal cancer disease survival,” Current Oncology, vol. 23, no. 2, pp. e116–e122, 2016. View at Publisher · View at Google Scholar · View at Scopus
  19. F. I. Cossor, L. L. Adams-Campbell, R. T. Chlebowski et al., “Diabetes, metformin use, and colorectal cancer survival in postmenopausal women,” Cancer Epidemiology, vol. 37, no. 5, pp. 742–749, 2013. View at Publisher · View at Google Scholar · View at Scopus
  20. M. M. J. Zanders, M. P. P. Van Herk-Sukel, P. A. J. Vissers, R. M. C. Herings, H. R. Haak, and L. V. Van De Poll-Franse, “Are metformin, statin and aspirin use still associated with overall mortality among colorectal cancer patients with diabetes if adjusted for one another?” British Journal of Cancer, vol. 113, no. 3, pp. 403–410, 2015. View at Publisher · View at Google Scholar · View at Scopus
  21. U. C. Mc Menamin, L. J. Murray, C. M. Hughes, and C. R. Cardwell, “Metformin use and survival after colorectal cancer: a population-based cohort study,” International Journal of Cancer, vol. 138, no. 2, pp. 369–379, 2016. View at Publisher · View at Google Scholar · View at Scopus
  22. T. Fransgaard, L. C. Thygesen, and I. Gögenur, “Metformin increases overall survival in patients with diabetes undergoing surgery for colorectal cancer,” Annals of Surgical Oncology, vol. 23, no. 5, pp. 1569–1575, 2016. View at Publisher · View at Google Scholar · View at Scopus
  23. C. R. Garrett, H. M. Hassabo, N. A. Bhadkamkar et al., “Survival advantage observed with the use of metformin in patients with type II diabetes and colorectal cancer,” British Journal of Cancer, vol. 106, no. 8, pp. 1374–1378, 2012. View at Publisher · View at Google Scholar · View at Scopus
  24. A. Stang, “Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses,” European Journal of Epidemiology, vol. 25, no. 9, pp. 603–605, 2010. View at Publisher · View at Google Scholar · View at Scopus
  25. D. Moher, A. Liberati, J. Tetzlaff, and D. G. Altman, “Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement,” International Journal of Surgery, vol. 8, no. 5, pp. 336–341, 2010. View at Publisher · View at Google Scholar · View at Scopus
  26. S. Y. Guraya, “Association of type 2 diabetes mellitus and the risk of colorectal cancer: a meta-analysis and systematic review,” World Journal of Gastroenterology, vol. 21, no. 19, pp. 6026–6031, 2015. View at Publisher · View at Google Scholar · View at Scopus
  27. Z. Nie, H. Zhu, and M. Gu, “Reduced colorectal cancer incidence in type 2 diabetic patients treated with metformin: a meta-analysis,” Pharmaceutical Biology, vol. 54, no. 11, pp. 2636–2642, 2016. View at Publisher · View at Google Scholar · View at Scopus
  28. X.-K. He, T.-T. Su, J.-M. Si, and L.-M. Sun, “Metformin is associated with slightly reduced risk of colorectal cancer and moderate survival benefits in diabetes mellitus: a meta-analysis,” Medicine, vol. 95, no. 7, Article ID e2749, 2016. View at Publisher · View at Google Scholar · View at Scopus
  29. S. Del Barco, A. Vazquez-Martin, S. Cufí et al., “Metformin: multi-faceted protection against cancer,” Oncotarget, vol. 2, no. 12, pp. 896–917, 2011. View at Publisher · View at Google Scholar · View at Scopus
  30. M. Yang, P. Liu, and P. Huang, “Cancer stem cells, metabolism, and therapeutic significance,” Tumor Biology, vol. 37, no. 5, pp. 5735–5742, 2016. View at Publisher · View at Google Scholar · View at Scopus
  31. V. C. Miranda, M. I. Braghiroli, L. D. Faria et al., “Phase 2 trial of metformin combined with 5-fluorouracil in patients with refractory metastatic colorectal cancer,” Clinical Colorectal Cancer, vol. 15, no. 4, pp. 321–328.e1, 2016. View at Publisher · View at Google Scholar · View at Scopus
  32. Z. B. Mei, Z. J. Zhang, C. Y. Liu et al., “Survival benefits of metformin for colorectal cancer patients with diabetes: a systematic review and meta-analysis,” PLoS ONE, vol. 9, no. 3, Article ID e91818, 2014. View at Google Scholar
  33. G. Anfossi, I. Russo, K. Bonomo, and M. Trovati, “The cardiovascular effects of metformin: further reasons to consider an old drug as a cornerstone in the therapy of type 2 diabetes mellitus,” Current Vascular Pharmacology, vol. 8, no. 3, pp. 327–337, 2010. View at Publisher · View at Google Scholar · View at Scopus